Kymera Therapeutics

Kymera Therapeutics Presents First Validation of IRAK4 Protein Degraders in MYD88-Mutant Lymphoma

Data Presented at the 2018 American Society of Hematology Annual Meeting Cambridge, Mass. (Dec. 3, 2018) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, today announced research demonstrating preclinical